Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952078 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
A Phase 1 study of T-Cell Lymphoma, sponsored by Corvus Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 20
- Study locations
NCT03952078: Active Phase 1 study of T-Cell Lymphoma, sponsored by Corvus Pharmaceuticals.
NCT03952078 is a Phase 1 study of T-Cell Lymphoma that is active but no longer recruiting, run by Corvus Pharmaceuticals. The registered enrollment target is 151 participants, above the 124-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03952078, a Phase 1 study of T-Cell Lymphoma, is active but no longer recruiting, sponsored by Corvus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Conditions Studied
Interventions
- DRUG CPI-818
Study Locations (20)
Gyeonggido
- Seoul National University Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- Seoul St. Mary's Hospital - Seoul
Beijing Municipality
- Beijing Friendship Hospital - Beijing
- Beijing Boren Hospital - Beijing
- Beijing Cancer Hospital - Beijing
New South Wales
- Concord Repatriation General Hospital - Concord
- Liverpool Hospital - Liverpool
California
- Stanford University - Palo Alto
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What the registry record for NCT03952078 still lists
NCT03952078 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (22% higher).
The record links to 1 condition, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CPI-818 is the first listed.
NCT03952078 names 20 study sites across 14 states, led by Gyeonggido, Beijing Municipality, New South Wales.
Frequently Asked Questions
What is clinical trial NCT03952078 about?
NCT03952078 is a clinical study titled "A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma". This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
What is the current status of trial NCT03952078?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2019-05-03. Estimated completion is 2026-04-30.
What conditions does trial NCT03952078 study?
This clinical trial studies the following conditions: T-Cell Lymphoma.
What interventions are being tested in trial NCT03952078?
The interventions under investigation include: CPI-818 (DRUG).
Who is sponsoring clinical trial NCT03952078?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03952078 being conducted?
This trial has 20 study locations across California, Michigan, Missouri, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03952078's enrollment target sits among peer trials
151 4th of 15 higher than 12 of 15 other T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of Tazemetostat in Lymphoid Malignancies
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CD4CAR for CD4+ Leukemia and Lymphoma
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI